Search Results
Dr. Smith on Frontline Treatment Options in MCL
Dr. Smith on Safety Profiles of BTK Inhibitors in MCL
Dr. Leslie on the Current Frontline Treatment Landscape in MCL
Dr. Martin on the Frontline Treatment Landscape of MCL
Dr. Smith on Frontline Treatment Considerations in CLL
Dr. Goy on the Evolution of Treatment Selection in MCL
Dr. Smith on Emerging Therapies in Indolent Lymphoma
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL
Exploring Subsets of Patients With Mantle Cell Lymphoma
Venetoclax Resistance: Mechanisms and Treatment Options
New Agents for Mantle Cell Lymphoma
Dr. Gerson on Clinical Trial Accrual in MCL